CA72-4 as a Promising Prognostic and Diagnostic Biomarker in Iraqi Patients with Colorectal Cancer

Authors

  • Mortada Basheer Sabbar Department of Microbiology, College of Medicine, University of Baghdad, 10049 Baghdad, IRAQ. https://orcid.org/0009-0006-2334-2574
  • Sarmad Mohammad Zeiny Department of Microbiology, College of Medicine, University of Baghdad, 10049 Baghdad, IRAQ. https://orcid.org/0000-0002-1976-9157
  • Mazin Judy Ibrahim Department of Oncology, College of Medicine, University of Baghdad, 10049 Baghdad, IRAQ.

DOI:

https://doi.org/10.23851/mjs.v34i1.1198

Keywords:

CA72-4, CEA, colorectal cancer, maker, ELISA

Abstract

Colorectal cancer (CRC), the second most fatal cancer and the 3rd most common cancer is expected to cause 0.9 million deaths globally in 2025. Carcinoembryonic antigen (CEA) is currently used in the follow-up of patients with colorectal cancer, and in this study, we are trying to find a better marker than CEA in following up on patients' health and knowing the effectiveness of the treatment used and as a diagnostic marker for colorectal cancer. To determine the significance of Cancer antigen 72-4 (CA72-4) as a prognosis predictor in patients with colorectal cancer, compare its prognostic validity to the CEA biomarker. this case-control study includes (150) participants, 100 patients (59 males and 41 females), and 50 healthy controls (26 males, 24 females). Blood samples were collected from all participants to measure the serum concentrations of CA72-4 and CEA using an enzyme-linked immunosorbent assay (ELISA). Between November 2020 and February 2021 in Baghdad, Iraq, this investigation was conducted at the oncology teaching hospital's gastrointestinal consulting clinic. There was a strong positive relation between CA242 and CEA (R = 0.953, p <0.001) and participants with colorectal cancer had considerably greater levels of CA72-4 than healthy controls (p <0.001). AUC was 0.944, sensitivity was 86%, specificity was 94%, and the cutoff value was 50 U/ml for the CA72-4. while AUC was 0.919, sensitivity was 91%, specificity was 80%, and the cutoff value was 5 ng/ml for the CEA.CA72-4 can serve as a potential prognostic and diagnostic biomarker for colorectal cancer.

Downloads

Download data is not yet available.

References

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.

CrossRef | PubMed

Andrea, N., Sue, T., & Rajendra, K. (2014). Value of Monitoring Cea in Patients with Colon Cancer Receiving Adjuvant Chemotherapy. Annals of Oncology, 25(2), ii75.

CrossRef

Alrubaiaee, S. A. K. T., & Jawad Kadhim Al-taee, T. (2022). Detection of BRAFV600E Biomarker in Patients With Colorectal Cancer Using Immunohistochemical Techniques/Clinico-Pathological Study. Journal of the Faculty of Medicine Baghdad, 64(1), 47-51.

CrossRef

Aljarshawi, M., Albadree, H., Bahar, H., & Al-Imam, A. (2021). Misleading Presentation of Colorectal Cancer in an Otherwise Healthy Patient. Journal of the Faculty of Medicine Baghdad, 62(4), 132-138.

CrossRef

Dhahir, N. K., & Noaman, A. A. (2021). A Comparative Study of Colorectal Cancer Based on Patient's Age. Journal of the Faculty of Medicine Baghdad, 63(2), 70-73.

CrossRef

H. Mahmood, A., M.H. Zeiny, S., & Sh. Mahmood, A. (2017). Serological markers "CEA test & sAPRIL test" in Iraqi patients with colon cancer. Journal of the Faculty of Medicine Baghdad, 59(4), 317-320.

CrossRef

Al-saady, R. K. (2012). Determination of Cancer Antigen CA15-3 and Carcino Embryonic Antigen CEA concentration as Tumor Markers in Patients with Stomach and Colorectal cancers. 54(3), 256-258.

Hu, P. J., Chen, M. Y., Wu, M. S., Lin, Y. C., Shih, P. H., Lai, C. H., & Lin, H. J. (2019). Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: A multicenter retrospective study. Cancers, 11(5), 1-8.

CrossRef | PubMed

Sabbar, M. B., Zeiny, S. M., & Ibrahim, M. J. (2022). Ca242 as a potential prognostic marker in colorectal cancer Iraqi patients. International Journal of Health Sciences, 6(S7), 473-486.

CrossRef

Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020). Colorectal cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(3), 145-164.

CrossRef | PubMed

Vuik, F. E. R., Nieuwenburg, S. A. V., Bardou, M., Lansdorp-Vogelaar, I., Dinis-Ribeiro, M., Bento, M. J., Zadnik, V., Pellisé, M., Esteban, L., Kaminski, M. F., Suchanek, S., Ngo, O., Májek, O., Leja, M., Kuipers, E. J., & Spaander, M. C. W. (2019). Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut, 1820-1826.

CrossRef | PubMed

Abancens, M., Bustos, V., Harvey, H., McBryan, J., & Harvey, B. J. (2020). Sexual Dimorphism in Colon Cancer. Frontiers in Oncology, 10(December), 1-27.

CrossRef | PubMed

White, A., Ironmonger, L., Steele, R. J. C., Ormiston-Smith, N., Crawford, C., & Seims, A. (2018). A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer, 18(1), 1-11.

CrossRef | PubMed

Hussein, A. A., Al-Janabi, S., Naseer, Z. H., & Hamody, T. A. (2017). Epidemiological Study of Cancers in Iraq-Karbala from 2008 to 2015. International Journal of Medical Research & Health Sciences, 6(1), 79-86.

Limsui, D., Vierkant, R. A., Tillmans, L. S., Wang, A. H., Weisenberger, D. J., Laird, P. W., Lynch, C. F., Anderson, K. E., French, A. J., Haile, R. W., Harnack, L. J., Potter, J. D., Slager, S. L., Smyrk, T. C., Thibodeau, S. N., Cerhan, J. R., & Limburg, P. J. (2010). Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. Journal of the National Cancer Institute, 102(14), 1012-1022.

CrossRef | PubMed

Kastrinos, F., Samadder, N. J., & Burt, R. W. (2020). Use of Family History and Genetic Testing to Determine Risk of Colorectal Cancer. Gastroenterology, 158(2), 389-403.

CrossRef | PubMed

Fang, Y. J., Lee, L. J. H., Luo, K. H., Fang, P. S., Yang, C. C., & Chuang, H. Y. (2022). The Association of Carcinoembryonic Antigen (CEA) and Air Pollutants-A Population-Based Study. Atmosphere, 13(3), 1-11.

CrossRef

Zhai, H., Huang, J., Yang, C., Fu, Y., & Yang, B. (2018). Serum CEA and CA19-9 levels are associated with the presence and severity of colorectal Neoplasia. Clinical Laboratory, 64(3), 351-356.

CrossRef | PubMed

Saito, G., Sadahiro, S., Kamata, H., Miyakita, H., Okada, K., Tanaka, A., & Suzuki, T. (2017). Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence. Oncology, 92(5), 276-282.

CrossRef | PubMed

Andrea, N., Sue, T., & Rajendra, K. (2014). Value of Monitoring Cea in Patients with Colon Cancer Receiving Adjuvant Chemotherapy. Annals of Oncology, 25(2), ii75.

CrossRef

Luo, H., Shen, K., Li, B., Li, R., Wang, Z., & Xie, Z. (2020). Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer. Oncology Letters, 20(1), 742-750.

CrossRef | PubMed

Huang, X., Lan, Y., Li, E., Li, J., Deng, Q., & Deng, X. (2021). Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer. Journal of International Medical Research, 49(5).

CrossRef | PubMed

Mariampillai, A. I., Cruz, J. P. Dela, Suh, J., Sivapiragasam, A., Nevins, K., & Hindenburg, A. A. (2017). Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract, lung, breast and ovaries. Anticancer Research, 37(7), 3649-3656.

Xu, Y., Zhang, P., Zhang, K., & Huang, C. (2021). The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochimica et Biophysica Acta - Reviews on Cancer, 1876(2), 188634.

CrossRef | PubMed

Downloads

Key Dates

Published

30-03-2023

Issue

Section

Original Article

How to Cite

[1]
M. B. Sabbar, S. M. . Zeiny, and M. J. . Ibrahim, “CA72-4 as a Promising Prognostic and Diagnostic Biomarker in Iraqi Patients with Colorectal Cancer”, Al-Mustansiriyah J. Sci., vol. 34, no. 1, pp. 10–15, Mar. 2023, doi: 10.23851/mjs.v34i1.1198.

Similar Articles

1-10 of 142

You may also start an advanced similarity search for this article.